Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow RenovoRx, Inc.

Get SEC filing alerts via email and in your feed for RenovoRx, Inc.

RNXT

RenovoRx, Inc.

About RenovoRx, Inc.

RenovoRx, Inc. is a life sciences company specializing in targeted drug delivery for difficult-to-treat cancers. Its core product, RenovoCath, is an FDA-cleared device utilizing the proprietary TAMP platform to precisely deliver chemotherapy directly to tumors, minimizing systemic toxicity. The company develops innovative drug-device combinations, with a focus on pancreatic and other solid tumors, serving oncology and interventional radiology markets through clinical trials and commercialization efforts.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from RenovoRx, Inc.

1
1
RenovoRx, Inc. RenovoRx Reports 186% Revenue Growth to $563,000 in Latest Quarter

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
RenovoRx, Inc. RenovoRx Reports 2,512% Revenue Growth to $1.1 Million, Faces Increased Losses

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
RenovoRx, Inc. RenovoRx Reports Revenue Growth and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
RenovoRx, Inc. RenovoRx Reports Revenue Growth to $422,000 in Q2 2025 Amid Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
RenovoRx, Inc. RenovoRx Reports First Revenue of $197,000 from RenovoCath in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
RenovoRx, Inc. RenovoRx Reports First Revenue of $43,000 and $8.8 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
RenovoRx, Inc. RenovoRx Reports Improved Financials, Raises $17.2M in Private Placements, and Advances Clinical Trials

Via official filing (AI summary) | over 1 year ago | 0 comments